Irisin is a predictor of sarcopenic obesity in type 2 diabetes mellitus

A cross-sectional study

Ayten Oguz, MD\textsuperscript{a,}*, Murat Sahin, MD\textsuperscript{b}, Dilek Tuzun, MD\textsuperscript{d}, Ergul B. Kurutas, PhD\textsuperscript{c}, Cansu Ulgen, MD\textsuperscript{d}, Ozlem Bozkus, PhD\textsuperscript{c}, Kamile Gul, MD\textsuperscript{a}

Abstract
We aimed to evaluate sarcopenia and sarcopenic obesity (SO) in patients with type 2 diabetes mellitus (T2DM), possible relationships with serum irisin and myostatin levels, and the effect of glycemic control on SO.

Ninety T2DM patients were included in this a cross-sectional study. Sarcopenia was determined by evaluating muscle mass (bioelectrical impedance analysis), muscle strength (HGS), and gait speed (GS). Patients with muscle mass loss with functionally reduced muscle strength and/or performance were considered sarcopenic. In addition, participants were divided into 3 groups according to the FM (fat mass)/FFM (fat-free mass) ratio [group 1:5th-50th percentiles; group 2:50th-95th percentiles and group 3: ≥95 percentiles (sarcopenic obese)]. Irisin, myostatin levels and metabolic parameters were measured in all patients.

The prevalence of sarcopenia and SO was 25.6% and 35.6%, respectively. Irisin levels were lower in sarcopenic patients, while glycosylated hemoglobin (A1c), body mass index (BMI), FM, and FM index were higher (\(P < .05\)). From group 1 to group 3, BMI, FM, FM index, GS, myostatin, and A1c increased, and muscle mass percentage, HGS, and irisin decreased (\(P < .05\)). A positive correlation was found between FM/FFM and myostatin and a negative correlation between FM/FFM and irisin (\(r = 0.303, P = .004\) vs. \(r = –0.491, P < .001\)). Irisin remained an important predictor of SO, even after adjusting for confounding variables (OR:1.105; 95% CI:0.965–1.338, \(P = .002\)). The optimal cut-off value for irisin to predict SO was 9.49 ng/mL (specificity = 78.1%, sensitivity = 75.8%).

In addition, A1c was an independent risk factor for SO development (OR:1.358, \(P = .055\)).

This study showed that low irisin levels (<9.49ng/mL) and poor glycemic control in T2DM patients were an independent risk factor, especially for SO.

Abbreviations: A1c = Glycosylated hemoglobin, ALT = Alanine aminotransferase, ASM = Appendicular skeletal muscle mass, BIA = Bioelectrical impedance analysis, BMI = Body mass index, CC = Calf circumference, CI = Confidence Interval, Cr = Creatinine, CV = Coefficients of variability, ELISA = Enzyme-linked immunosorbent assay, FFM = Fat-free mass, FMFI = Fat-free mass index, FM = Fat mass, FMI = Fat mass index, GS = Gait speed, HC = Hip circumference, HDL-C = High density lipoprotein, HGS = Hand-grip strength, HPLC = High-pressure liquid chromatography, IR = Insulin resistance, LDL-C = Low density lipoprotein, MAC = Mid-arm circumference, OR = Odds Ratio, ROC = Receiver operating characteristic, SD = Standard deviation, SMI = Skeletal muscle index, SO = Sarcopenic obesity, T2DM = Type 2 diabetes mellitus, TG = Triglyceride, Total-C = Total cholesterol, WC = Waist circumference, WHR = Waist-to-hip ratio.

Keywords: body composition, myokine, obesity, type 2 diabetes

1. Introduction
Body composition changes with aging, muscle mass and muscle strength decrease, and body fat percentage increases. Sarcopenia is defined as a generalized loss of muscle mass and strength that may cause health problems.\cite{1,2} Patients with type 2 diabetes mellitus (T2DM) have a higher risk.\cite{3,4} Recently, the definition...
of sarcopenic obesity (SO), which includes both sarcopenia and obesity, has also emerged. Sarcopenic obesity is a clinical and functional condition characterized by the association of sarcopenia, in which lean body mass decreases and fat mass (FM) increases, causing more serious metabolic disorders than obesity and sarcopenia alone. SO is also more common in patients with T2DM.[5-7]

Myostatin is a member of the transforming growth factor-β family, and although it is abundant in muscles, it is also found in small amounts in adipose tissue and heart muscle.[8] Some studies revealed an association between increased myostatin levels and increased age, decreased muscle mass, and muscle strength.[9,10] In addition, high myostatin levels have been shown to be associated with obesity and insulin resistance (IR).[11,12]

Irisin is a myokine that is released by skeletal muscles and is a potential biomarker for sarcopenia.[13] Myostatin inhibition has been shown to increase irisin levels in animal studies.[14] Furthermore, irisin has been associated with decreased body weight and increased insulin sensitivity.[15] In sarcopenic individuals, circulating irisin levels have been shown to be lower and therefore recommended as a potential marker for sarcopenia.[13,16]

T2DM is associated with a rapid loss of skeletal muscle mass and strength.[3,4] Some studies have shown an association between sarcopenia and diabetes duration and poor glycemic control.[17,18] It has even been suggested that sarcopenia has the third complication in addition to the microvascular and macrovascular complications of diabetes.[19] However, the causal relationship between SO and glycemic control remains unclear.

Sarcopenic obesity has different definitions. Diagnostic criteria and limits are not universally defined.[19,20] However, several recent studies have suggested using the FM/fat-free mass (FFM) ratio for defining SO. FM/FFM is a more integrated index for the evaluation of abnormal body composition than indices of each individual component.[12,21]

Our aim was to evaluate the factors related to sarcopenia and SO in T2DM patients and to explore its association with serum levels of myostatin and irisin.

2. Material and methods

This cross-sectional study was conducted at the Endocrinology and Metabolism and Medical Biochemistry Clinics of Kahrmanmaras Sutcu Imam University. The local ethics committee approved the observational cross-sectional study (dated: February 20, 2019; decision number:18), and written informed consent was obtained from all subjects.

2.1. Study protocol and inclusion criteria

Sample size calculations were performed using the G power analysis system.[22] 93 T2DM patients (admitted to the endocrinology outpatient clinic) between the ages of 18–70 and a body mass index (BMI) of 25–40 kg/m² were included in the study. Sociodemographic data, medications, comorbidities, chronic vascular complications, and diabetes self-management parameters (blood glucose measurements, dietary compliance, and exercise) of all patients were recorded.

The patients included in the study were evaluated according to muscle mass and muscle strength and/or performance[11] (Fig. 1). In addition, irisin and myostatin levels and metabolic parameters were measured in all patients.

2.2. Exclusion criteria

Patients that use non-steroid anti-inflammatory drugs or prednisolone (>7.5 mg/day) and have contraindications for bio-impedance analysis (BIA) (e.g., pacemaker) were excluded from the study. Patients with type 1 diabetes, renal impairment (estimated glomerular filtration rate <15 ml/min/1.73 m²), renal replacement therapy, pregnancy, infectious diseases, muscular dystrophy, lipodystrophy and cancer, Cushing syndrome, growth hormone, and severe vitamin D deficiency (<10 ng/ml), hypogonadism, hypothyroidism, and hyperthyroidism that could cause sarcopenia were also excluded.

2.3. Anthropometric measurements

During weight measurement, patients had light clothes and measurements were made with 0.1 a sensitivity. Height (m) was measured using a wall-mounted meter with a 0.1 cm sensitivity. We measured the waist circumference (WC) by locating the hip bone and the top of the right iliac crest, and then placing a measuring tape in a horizontal plane around the abdomen at the level of the iliac crest.[23] Hip circumference (HC) (cm) was measured from the widest part of the hip. The waist-to-hip ratio (WHR) was calculated as the ratio of waist circumference to hip circumference. The bilateral maximum calf circumference (CC) and middle arm circumference (MAC) were also measured. MAC was measured at the midpoint between the olecranon process of the ulna and the acromion process of the scapula. CC was measured as the maximum horizontal distance around the left calf as the subject stood upright.[24]

2.4. Body composition measurements

Body composition was measured using a BIA-device (TANITA DC 360 ST, Japan). Patients were asked not to eat, not to drink and not to undertake any physical activity at least three hours before the test and to void the bladder immediately before the measurement. FM (kg), FFM (kg), and appendicular skeletal muscle (ASM) (kg) were measured using BIA.

The skeletal muscle index (SMI) was calculated as ASM (kg)/height² (kg/m²).[11]

ASM (%) was calculated as ASM (kg)/body kg × 100. The cut-off point for low ASM (%) was <37.0% for men and <27.6% for women.[27]

FM index (FFMI), FFM/height² (kg/m²), and FM index (FMI) were calculated as FM/height² (kg/m²).[11]

2.5. Muscle strength evaluation

Muscle strength was evaluated using a hand-grip dynamometer (Kyto EH 101, Guangdong, China). While taking the measurement, the patients were asked to stand upright, and they were asked to grasp and tighten the tool with all their strengths. The measurement was performed three times from both hands (right and left), and the mean of these values was recorded.[28] The hand grip strength (HGS) measurement results were taken as kg and the device is sensitive to 0.1 kg and can make measurements between 5–90 kg.

Cut-off values for low mass strength according to HGS were adjusted to BMI were as follows: ≤29 kg, ≤30 kg, ≤30 kg, and ≤32 kg (according to these BMI groups, ≤24, 24.1–26, 26.1–28, and > 28 kg/m², respectively) for males and ≤17 kg, ≤17,3 kg.
≤18 kg, and ≤21 kg (according to these BMI groups, 23, 23.1–26, 26.1–29, and >29 kg/m², respectively) for females.²⁹

Poor physical performance was evaluated using a gait speed (GS) test (6m). In this test, the participants were requested to walk at their own pace in a pre-measured area of 6 m. The duration was started with the person’s foot at the start line and ended when it crossed the finish line. Two measurements were performed, and the best result was recorded in seconds (s).³⁰ The GS scores were adjusted for height. Cutoff values for poor physical performance were GS ≥ 7s (height ≤173 cm) and GS ≥ 6s (height >173 cm) for males and GS ≥ 7s (height ≤159 cm) and GS ≥ 6s (height >159 cm) for females.²⁹

2.6. Definition of sarcopenia and sarcopenic obesity:
Participants were identified as being “not sarcopenic” or “sarcopenic” using the criteria recommended by the European Working Group on Sarcopenia in Older People.¹ Participants with muscle mass loss with functionally reduced muscle strength and/or performance were considered sarcopenic. As the patients included in the study were overweight/obese, we used ASM (%) as the muscle mass while defining sarcopenia.⁷

The FM/FFM ratio is an index of the SO. Participants were divided into 3 groups according to the FM/FFM ratio and used the following cut-off values (5th-95th percentiles) from National Health and Nutrition Examination Survey III obtained using BIA.³¹ Participants were divided into 3 groups according to FM/FFM values (adjusted to gender, BMI and age).

Group 1 (control); cut-off values for FM/FFM (5th-50th percentiles) were <0.34, <0.43, <0.34, <0.42; <0.36, <0.43 (according to BMI 25–29.9 and 30–39.9 kg/m², respectively) for 18–40, 40–60 and 60–70 years males and <0.59, <0.76; <0.62, <0.77; <0.63, <0.76 (according to BMI 25–29.9 and 30–39.9 kg/m², respectively) for 18–40, 40–60 and 60–70 years females.

Group 2; increase in FM are small relative to those in FFM. Cut-off values for FM/FFM (50th-95th percentiles) were 0.34–0.46, 0.43–0.57; 0.34–0.47, 0.42–0.59; 0.36–0.50, 0.43–0.59 (according to BMI 25–29.9 and 30–39.9 kg/m², respectively) for 18–40, 40–60 and 60–70 years males and 0.59–0.74, 0.76–1.01; 0.62–0.76, 0.77–0.93; 0.63–0.76, 0.76–0.97 (according to BMI 25–29.9 and 30–39.9 kg/m², respectively) for 18–40, 40–60 and 60–70 years females.

Group 3; SO phenotypes, where FM is greatly increased and FFM is decreasing. Cut-off values for FM/FFM (≥95th percentiles) were >0.46, >0.57; >0.47, >0.59; <0.50, >0.59 (according to BMI 25–29.9 and 30–39.9 kg/m², respectively) for 18–40, 40–60 and 60–70 years males and >0.74, >1.01; >0.76, >0.93; >0.76, >0.97 (according to BMI 25–29.9 and 30–39.9 kg/m², respectively) for 18–40, 40–60 and 60–70 years females.

ASM, appendicular skeletal muscle mass; GS, gait speed; HGS, hand grip strength

Figure 1. The selection of participants and evaluation for sarcopenia.
2.7. Biochemical measurements

Blood samples for biochemical parameters were taken from the antecubital vein between 08:00–09:00 in the morning after 8–10h of fasting. Glucose, alanine aminotransferase (ALT), creatinine (Cr), and lipid parameters were measured by spectrophotometry using the Advia 1800 Chemistry System (Siemens, Germany). Glycosylated hemoglobin (A1c) was measured using a high-pressure liquid chromatography (HPLC) device and a commercial kit (BioRad D-10 Hemoglobin Testing System, France). Spot urine Cr levels were measured based on the reaction of Cr with picric acid using a biochemistry analyzer and commercial kit (ADVIA Chemistry Cr Concentrated CRE_2c). Urine protein/Cr levels were expressed as mg/gr.

Spot urine Cr levels were measured based on the reaction of Cr with picric acid using a biochemistry analyzer and commercial kit (ADVIA Chemistry Cr Concentrated CRE_2c). Urine protein/Cr levels were expressed as mg/gr. Normal reference values were as: total cholesterol (Total-C) 0–200 mg/dl, triglyceride (TG) 0–150 mg/dl, high density lipoprotein (HDL-C) 26–86 mg/dl, low density lipoprotein (LDL-C) 0–130 mg/dl, ALT 7–45 U/L, Cr 0.5–0.9 mg/dl, and spot urine protein/Cr 50–200 mg/gr, irisin 3.12–200 ng/ml and myostatin 3.12–100 ng/ml.

2.8. Statistical analysis

Data are presented as the mean ± standard deviation (SD), unless otherwise specified. Data were analyzed using IBM SPSS (Statistical Package for Social Sciences) version 25. The Kolmogorov–Smirnov test was used to determine whether the samples had a normal distribution and whether the variances were homogeneous. An independent 2 Sample t-test was used to compare the two groups in the data with normal distribution, and the Mann–Whitney U test, a nonparametric test, was used in the data without normal distribution. A one-way ANOVA test was used to evaluate more than two groups. Data that differed between the groups were evaluated using post-hoc analysis. If the variance analysis was homogeneous, the group number was three, but the sample was not equal, and the Scheffe method was used to evaluate the difference in significance in the post-hoc analysis. The direct relationship between the variations was evaluated using Pearson’s and Spearman’s correlation tests. The chi-square test was used to evaluate the association between the frequency distribution of categorical variables. Logistic regression analysis was performed to determine the effects of clinical and laboratory variables on SO. The variables found to be statistically significant in the univariate analysis and other potential confounders were used in the multiple logistic regression model with the enter method to determine the independent prognostic factors of SO. Relative odds were expressed as odds ratios (ORs) and confidence intervals (CIs). Statistical significance was set at P < .05. The values of the predicted irisin levels and 95% CIs were computed. After performing the antilogarithmic transformation, the cutoff values and 95% CIs were determined.

3. Results

Initially, 93 patients were included in the study, but three patients were excluded because of missing data. This study included 90 patients, 22.2% (n = 20) male and 77.8% (n = 70) female (Fig. 1).

3.1. Sarcopenia evaluation

When the patients included in the study were evaluated according to muscle mass and muscle strength and/or performance, the rate of sarcopenia was 25.6% (n = 23). When analyzed by sex, 15.0% (n = 3) of men and 28.6% (n = 20) of women were sarcopenic, but the difference was statistically insignificant (P = .201). The percentage of patients with low muscle mass for men and women (15.0% vs 11.4%) and poor physical performance (high GS (s) for men and women, 30.0% and 54.0%, respectively) between males and females were insignificant (P = .460 vs P = .086). The percentage of patients with low HGS (kg) was significantly higher in men than in women (54.3% vs 25.0%, respectively, P = .018).

There was no statistically significant difference between sarcopenic and non-sarcopenic type 2 diabetic patients in terms of baseline characteristics (Table 1).

| Parameters | Non-sarcopenic (n = 67, 74.4%) | Sarcopenic (n = 23, 25.6%) | P |
|------------|-------------------------------|--------------------------|---|
| Age (years) | 55.01 ±8.81 | 54.17 ±7.68 | .685 |
| Gender n, (%) | | | |
| Female | 50 (71.4) | 20 (28.6) | .201 |
| Male | 20 (28.6) | 3 (15.0) | .460 |
| DM duration (years) | 10.97 ±6.74 | 11.26 ±6.03 | .848 |
| Smoking, n (%) | 4 (6.0) | 1 (4.3) | .909 |
| Education level, n (%) | | | |
| < Elementary school | 50 (74.6) | 20 (87.0) | .201 |
| ≥ Elementary school | 17 (25.4) | 3 (13.0) | | |
| Medication, n (%) | | | |
| OAD | 26 (38.8) | 7 (30.4) | .468 |
| Insulin | 41 (61.2) | 16 (69.6) | .617 |
| Statin | 43 (64.2) | 16 (69.6) | .962 |
| MIVC, n (%) | | | |
| Neuropathy | 36 (53.7) | 13 (56.5) | .816 |
| Retinopathy | 17 (25.4) | 9 (39.1) | .217 |
| Nephropathy | 3.0 (4.5) | 1.0 (4.3) | .731 |
| MAVC, n (%) | | | |
| ASCVD | 19 (28.4) | 8 (34.8) | .189 |
| PAD | 1 (1.5) | 1 (4.3) | .633 |
| CVD | 1 (1.5) | 1 (4.3) | .633 |
| Comorbidities, n (%) | | | |
| Hypertension | 40 (59.7) | 14 (60.9) | .921 |
| Hyperlipidemia | 46 (68.7) | 18 (78.3) | .371 |
| Obesity | 52 (77.6) | 21 (91.3) | .125 |
| Diabetes self-management, n (%) | | | |
| SMBG | 39 (58.2) | 14 (60.9) | .823 |
| Diet compliance | 32 (47.8) | 11 (47.8) | .996 |
| Exercises | 23 (34.3) | 7 (30.4) | .802 |

Data are presented as n (%) and mean ± standard deviation.
T2DM = Type 2 Diabetes Mellitus; OAD = oral antidiabetics; MIVC = microvascular complications; MAVC = macrovascular complications; ASCVD = atherosclerotic cardiovascular disease; PAD = peripheral arterial disease; CVD = cerebrovascular disease; SMBG = Self Management Blood Glucose Monitoring.
When sarcopenic and non-sarcopenic T2DM patients were compared in terms of anthropometric, body composition, and laboratory parameters (Table 2), mean BMI, WC, HC, FM, FMI, and CC were higher in sarcopenic patients (P = .003, P = .025, P = .013, P = .017, P = .002, and P = .001), but ASM (%), (P = .002), and HGS (P = .009) were lower in sarcopenic patients. A1c levels were higher in sarcopenic patients, and the rate of patients above target A1c (≥7%) was significantly higher in the sarcopenic group (P = .016 vs P = .002).

### 3.2. Evaluation of sarcopenic obesity

The patients included in the study were divided into three groups: group 1 (n = 24, 26.7%), group 2 (n = 34, 37.8%), and group 3 (SO) (n = 32, 35.6%) according to the FM/FFM rate (Table 3). In terms of gender, the male ratio was higher in group 1, but the female ratio was higher in groups 2 and 3 (P < .001) (Fig. 2). From group 1 to group 3, BMI, WC, HC, CC, MAC, FM, FMI, (%) FM/FFM, FMI, GS, A1c, and total-C increased (P < .001, P < .001, P < .001, P < .001, P < .001, P < .001, P < .001, P < .001, P = .009 and P = .032, respectively), but ASM (kg), ASM (%), FFM (%), FMMI and HGS were decreased, and the differences were statistically significant (P < .004, P < .001, P < .001, P = .019 and P < .001, respectively).

In post hoc analysis, BMI, WC, HC, FM, FMI, (%) FM/FFM, FMI were higher (P < .001, P = .008, P < .001, P < .001, P < .001 vs P < .001, P < .001, P < .001, P < .001, P < .001, P < .001, P < .001, P < .001, P < .001, P = .006 vs P < .001, P < .001, P < .001). In addition, CC, MAC, GS, total-C and A1c levels were significantly higher in group 3 than in group 1 (P < .001, P < .001, P = .010, and P = .010, respectively), BMI, WC, HC, CC, MAC, FM, (%) FMI and GG were significantly higher (P < .001, P = .008, P < .001, P < .001, P < .001, P < .001, P = .018, respectively), and FFM (%) and ASM (%) was significantly lower in group 3 than in group 2 (P < .001 vs P < .001).

The relationship between demographic, anthropometric, and metabolic parameters and sarcopenia and SO markers in T2DM patients is shown in Table 4. There was a positive correlation between FMI/FFMI and BMI, WC, HC, FM, FMI, (%) A1c, (%) WS, (%) CC, MAC, total-C, and A1c levels (r = 0.966, r = 0.301, r = 0.841, r = 0.589, r = 0.589, r = 0.250, r = .017 and r = 0.250, P = .015, respectively), and a negative correlation between FMI/FFMI with ASM (%), FMI, and HGS (r = -0.980, r = -0.310, r = .003 and r = -0.385, P < .001). A positive correlation was detected between ASM (%) and FMI, FMI, HGS (r = 0.311, P < .001 vs r = 0.426, P < .001), and a negative correlation was detected between ASM (%) and FMI, FMI, FMI, BMI, CC, MAC, total-C, and A1c (r = -0.947, P < .001, r = -0.988, P < .001, r = -0.296, P = .005, r = -0.815, P < .001, r = -0.564, P < .001, r = -0.552, P < .001, r = -0.281, P = .007 and r = -0.279, P = .008, respectively). There was a positive correlation between HGS and ASM (%), (r = 0.426, P < .001 vs r = 0.273, P = .009), negative correlation between HGS and FMI/FFMI, FMI, BMI, total-C, and A1c (r = -0.385, P < .001, r = -0.461, P < .001, r = -0.320, P = .002, r = -0.208, P = .049, r = -0.226, P = .032, and r = -0.259, P = .014, respectively). There was a positive correlation between GS and FMI/FFMI, FMI, A1c, and A1c (r = 0.301, P = .004, r = 0.323, P = .002, r = 0.290, P = .006 and r = 0.240, P = .023, respectively), and a negative correlation between GS, ASM (%), BMI, and HGS (r = -0.296, P = .005, r = -0.209, P = .048, and r = -0.320, P = .002, respectively).

### 3.3. Evaluation of myostatin and irisin

Myostatin levels were similar between patients with and without sarcopenia (P = .108). Irisin levels were significantly lower in patients with sarcopenia than in those without sarcopenia (P = .038) (Table 2). In the evaluation of SO, myostatin levels increased from group 1 to group 3 (P = .022), but irisin levels decreased (P < .001) (Table 3). In post hoc analysis, myostatin levels were higher (P = .058 vs P = .033) and irisin levels were lower (P < .001 vs P < .001) in groups 2 and 3 than in group 1. Irisin levels were significantly lower in group 3 than in group 2 (P = .004) (Fig. 3A&B).
We detected a positive correlation between FM/FFM and myostatin and a negative correlation between FM/FFM and irisin (r = 0.303, P = .004 vs r = −0.491, P < .001). There was a negative correlation between myostatin with ASM (%) and HGS (r = −0.351, P = .001 vs r = −0.270, P = .010). While irisin was positively correlated with ASM (%) and HGS (r = 0.494, P < .001 vs r = 0.354, P = .001), it was negatively correlated with FM/FFM and GS (r = −0.491, P < .001 vs r = 0.275, P = .009). There was a negative correlation between myostatin with FFMI and irisin with FMI (r = −0.326, P = .002 vs r = −0.428, P < .001) (Table 4).

3.4. Logistic regression and ROC analysis

In the multiple logistic regression model using the enter method, irisin (OR:1.105; 95% CI:0.965–1.338, P = .002) remained a significant predictor of SO after adjusting for confounding variables. In addition, A1c was an independent risk factor for SO development (OR:1.358, P = .004) (Table 5).

This receiver operating characteristic (ROC) curve shows that the optimal cut-off point of irisin in the prediction of SO was 9.49ng/mL, with a specificity of 78.1% and sensitivity of 75.8% (area under the curve = 0.797; 95% CI:0.703–0.892, P < .001) (Fig. 4).
4. Discussion

The measurement of body composition is important, especially in obesity, and BIA is a non-invasive method used for this purpose. It is recommended to use weight or height-adjusted ASM (ASM/body weight×100 = ASM (%)) or ASM/height ([kg/m²]=SMI) in the evaluation of low muscle mass in obese patients. Several studies have suggested the FM/FFM ratio in defining the SO. Since the patients included in our study had a BMI value of 25–40 kg/m², we demonstrated muscle mass loss with ASM (%) measured by BIA. We also determined low muscle strength with a low HGS and/or increased GS. We also defined SO using the FM/FFM ratio obtained using the BIA.

The prevalence of sarcopenia increases with age. Several studies have revealed an association between diabetes and sarcopenia, and the prevalence of sarcopenia increased 2–3 times in patients with diabetes than in healthy controls. However, information on the prevalence of SO in patients with T2DM is limited. In a study that included 198 patients with diabetes, the prevalence of sarcopenia was 29.3%. In another study involving diabetic patients, the prevalence of sarcopenia was found to be 28.8%, 35.6%, and 23.3% in men and women, respectively. In the Korean Sarcopenic Obesity Study, performed by Kim et al, the prevalence of sarcopenia was higher in patients with T2DM than in the control group (15.7% vs 6.9%). In another study, when evaluated by sex, the prevalence of SO was 16.7% in men and 5.7% in women with SMI defined sarcopenia; however, it was 35.1% in men and 48.1% in women by ASM (%) defined sarcopenia. Low et al reported the prevalence of SO defined by using the FM/FFM ratio as 19.4% in their study with 1235 T2DM patients. In our study, we found the total prevalence of sarcopenia to be 25.6%, while the SO prevalence was 35.6%. In terms of sex, the prevalence of sarcopenia was higher in females, but the difference was not statistically significant (28.6% vs 15.0%). The prevalence of SO was significantly higher in females than males (41.4% vs 15.0%). In terms of muscle function indicators, the rate of women with low HGS was higher than that of men (54.3% vs 25.0%). Our findings supported that sarcopenia and especially SO prevalence was higher in female patients with T2DM, similar to the literature. We think that the reason for the differences in the

| Variables | FM/FFM | ASMI (%) | FMI | FFMI | HGS | GS | Age | BMI | WHR | CC | MAC | FPG | T-C | LDL-C | HDL-C | TG | Cr | eGFR | Myostatin | Irsin | A1c |
|-----------|--------|----------|-----|------|-----|----|-----|-----|-----|----|-----|-----|----|-------|-------|----|----|------|-----------|------|-----|
| r         | −0.988 | 0.096   | 0.310 | 0.385 | 0.301 | 0.010 | 0.841 | 0.068 | 0.589 | 0.589 | 0.003 | 0.250 | 0.113 | 0.203 | 0.039 | 0.009 | 0.148 | 0.303 | −0.491 | 0.256 |
| p         | 0.000  | 0.000   | 0.003 | 0.004 | 0.026 | 0.027 | 0.015 | 0.070 | 0.000 | 0.000 | 0.000 | 0.000 | 0.980 | 0.017 | 0.279 | 0.055 | 0.007 | 0.841 | 0.004 | 0.000 | 0.154 |
| p         | 0.000  | 0.000   | 0.003 | 0.005 | 0.003 | 0.006 | 0.001 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.014 |
| r         | −0.385 | 0.026   | 0.046 | 0.073 | 0.000 | 0.030 | 0.001 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| p         | 0.000  | 0.000   | 0.009 | 0.009 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| r         | 0.301  | 0.296   | 0.323 | 0.320 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| p         | 0.004  | 0.005   | 0.046 | 0.046 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| r         | 0.966  | 0.947   | 0.169 | 0.461 | 0.209 | 0.090 | 0.945 | 0.160 | 0.683 | 0.689 | 0.017 | 0.232 | 0.127 | 0.190 | 0.009 | 0.014 | 0.009 | 0.121 | 0.428 | 0.185 |
| p         | 0.000  | 0.000   | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| r         | −0.310 | 0.311   | −0.169 | 0.273 | 0.323 | 0.138 | 0.128 | 0.023 | 0.112 | 0.081 | 0.083 | 0.036 | 0.180 | 0.188 | 0.173 | 0.224 | 0.012 | −0.326 | 0.176 | 0.265 |
| p         | 0.003  | 0.003   | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |

Figure 2. Sex distribution of groups according to FM/FFM.
prevalence of sarcopenia and SO in the studies is due to the heterogeneity of the diagnostic methods, definitions, and study populations used in the studies.

T2DM and obesity may have harmful effects on muscle mass and function. In contrast, in sarcopenia, skeletal muscle mass, which plays an important role in glucose metabolism, decreases, thereby increasing the risk of IR, obesity, and metabolic syndrome. In our study, BMI, WC, CC, FM, and FMI were significantly higher in patients with sarcopenia than in those without sarcopenia. In addition, we found a negative relationship between FMI, BMI and muscle mass, muscle strength, and a positive relationship between GS. Similar to the literature, our findings support that obesity negatively affects muscle mass and strength in type 2 diabetic patients.

Myostatin is a negative regulator of muscle mass, as well as a potential biomarker that contributes to both metabolic and anabolic defects in SO. Some studies have revealed an association between decreased myostatin levels and age, decreased muscle mass, and decreased muscle strength. Moreover, high myostatin levels have been shown to be associated with obesity and IR. It was observed that the circulating myostatin concentrations correlated with IR, myostatin expression and secretion increased in skeletal muscle and adipose tissue samples obtained from obese and severely obese women. Myostatin levels are increased in T2DM patients. In our study, myostatin levels were similar in patients with and without sarcopenia, which may be due to the low number of cases in our study. On the other hand, myostatin levels were significantly higher SO (group 3) than in the control group (group 1). There was a positive correlation between myostatin and FM/FMI and a negative correlation between myostatin and ASM (%), FFMI and HGS. Our data support that myostatin may be an influencing factor in SO.

Irisin is a myokine associated with increased energy expenditure due to its ability to stimulate browning of white adipose tissue, which is secreted after exercise. Irisin levels are reported to be low in obese individuals, patients with T2DM, and coronary artery disease. Liu et al showed that irisin levels were lower in long-standing T2DM patients than in non-diabetic controls. Another study found that circulating irisin

Table 5

Univariate and multiple logistic regression analyses for predicting sarcopenic obesity.

| Variables          | Univariate analysis | Multivariable analysis |
|--------------------|---------------------|------------------------|
|                    | P       | OR | 95% C.I. | P       | OR | 95% C.I. |
| Age (year)         | .578    | 1.015 | 0.964–1.068 | .055    | 1.015 | 0.964–1.068 |
| HGS (kg)           | .020    | 0.928 | 0.871–0.988 | .002    | 1.093 | 1.025–1.166 |
| GS (m/s)           | .002    | 1.569 | 1.176–2.092 | .001    | 1.302 | 1.100–1.540 |
| Total-C (mg/dL)    | .054    | 1.011 | 1.000–1.022 | .002    | 1.105 | 0.965–1.338 |
| Irisin (ng/mL)     | .000    | 1.302 | 1.038–1.616 | .055    | 1.358 | 0.993–1.857 |
| Myostatin (ng/mL)  | .334    | 0.984 | 0.953–1.016 | .334    | 0.984 | 0.953–1.016 |
| A1c (%)            | .010    | 1.378 | 1.080–1.757 | .055    | 1.358 | 0.993–1.857 |

All the variables related to sarcopenic obesity were examined (excluding anthropometric measurements) and only those significant at P < .05 level are used in univariate analysis. Multiple logistic regression analysis including all the variables in univariate analysis with enter method. P < .05 was considered statistically significant.

Non-significant variables in multiple logistic regression analysis were not indicated in the table.

95% CI = 95% confidence interval, A1C = glycosylated hemoglobin, B = regression coefficient, GS = gait speed, HGS = hand grip strength, OR = odds ratio, Total-C = total cholesterol.
levels were negatively correlated with BMI, WHR, and FM. Furthermore, a positive correlation has been reported between irisin levels and muscle mass and strength in humans and a negative correlation between irisin levels and fasting blood glucose levels. In our study, irisin levels were significantly lower in patients with sarcopenia. Irisin levels were significantly lower in SO group (group 3) than in the control and group 2. Additionally, we detected a positive correlation between irisin and muscle mass (ASM%) and muscle strength (HGS), while irisin were negatively correlated with poor physical performance (GS), FM/FFM and FMI. In our study, the level of irisin in the development of sarcopenia was an independent risk factor, even after correcting for diabetes-related clinical and laboratory confounding factors. We did not find a cut-off value for irisin for predicting diabetic SO in the literature. In our study, we found that a cut-off value of <9.49ng/mL may be a predictor for SO. Our findings suggest that irisin is an important marker for both sarcopenia and SO development in patients with T2DM.

Hyperglycemia also contributes to the development of sarcopenia. Several studies have revealed an association between poor glycemic control and sarcopenia. Park et al. showed that poor glycemic control (A1c > 8.0%) was associated with poorer muscle quality. Sugimoto et al. showed that there was a positive association between sarcopenia and A1c levels, and poor glycemic control was associated with low muscle mass. In our study, A1c levels were significantly higher in sarcopenic patients than in patients without sarcopenia, and A1c levels in 91.3% of sarcopenic patients were not targeted. Furthermore, there was a positive association between A1c, FM/FFM, and GS, and a negative association between A1c and muscle mass (ASM %), FFMI and muscle strength (HGS). A1c levels were significantly higher in the SO group than in the control group. In addition, A1c was an independent risk factor for SO development (OR: 1.358, P = .055). Therefore, the relationship between sarcopenia and SO and poor glycemic control may also be an indication that sarcopenia may be reversible after glycemic control is achieved. In a 6-month study, after glycemic control was achieved, a significant increase in muscle mass was observed.

As a result, in this study, we showed that myostatin and irisin are effective in sarcopenic and SO patients with type 2 diabetes. We determined that low irisin levels were an independent risk factor, especially for SO, and poor glycemic control (A1c ≥ 7%) had a negative effect on sarcopenia. Therefore, we believe that irisin can be used in the evaluation of SO in patients with type 2 diabetes and that glycemic control is an effective factor in preventing the development of sarcopenia.

4.1. Limitations and prospects

First, the sample size included in this study was relatively small, and we planned to increase the sample size in future studies.

Second, a prospective evaluation of the effect of establishing optimal glycemic control with diabetes treatment on the normalization of sarcopenia, irisin, and myostatin levels can be an important contribution.

Third, both irisin and myostatin can be measured using both ELISA and mass spectrophotometry. In our study, we measured both parameters (myostatin and irisin) using an ELISA device with commercial kits. Our results and standard graphics were fine. In our study, we did not compare the methods used for myostatin and irisin. However, these methods can be compared in future studies.

Fourth, although it is not the gold standard method for measuring body composition, we used BIA, which is an easily applicable noninvasive method. This may be a limitation of our study.

Author contributions

Conceptualization: Ayten Oguz.

Formal analysis: Ayten Oguz, Dilek Tuzun.

Funding acquisition: Ayten Oguz.

Investigation: Ergul Belge Kurutas, Cansu Ulgen, Ozlem Bozkus.

Methodology: Ayten Oguz, Dilek Tuzun.

Project administration: Ayten Oguz.

Resources: Ergul Belge Kurutas, Ozlem Bozkus.

Supervision: Kamile Gul.

Validation: Ergul Belge Kurutas, Ozlem Bozkus.

Visualization: Murat Sahin, Dilek Tuzun.

Writing – original draft: Ayten Oguz, Murat Sahin, Kamile Gul.

Writing – review & editing: Murat Sahin, Cansu Ulgen, Kamile Gul.

References

[1] Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48:16–31. doi: 10.1093/ ageing/afy169.

[2] Chen LK, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc 2020;21:300–7. e2. doi: 10.1016/j. jamda.2019.12.012.

[3] Seok WP, Goodpaster BH, Jung SL, et al. Excessive loss of skeletal muscle mass in older adults with type 2 diabetes. Diabetes Care 2009;32:1993–7. doi:10.2337/dc09-0264.
[4] Sinclair AJ, Abdelhafiz AH, Rodríguez-Mañas L. Frailty and sarcopenia—newly emerging and high impact complications of diabetes. J Diabetes Complications 2017;31:1465–73. doi:10.1016/j.jdiacomp.2017.05.003.

[5] Lim S, Kim JH, Yoon JW, et al. Sarcopenic obesity: prevalence and association with metabolic syndrome in the Korean Longitudinal Study on Health and Aging (KLSHA). Diabetes Care 2010;33:1652–4. doi:10.2337/dc10-0019. 10.2337/dc10-0019.

[6] Kim TN, Park MS, Yang SJ, et al. Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: The Korean Sarcopenic Obesity Study (KOSOS). Diabetes Care 2010;33:1497–9. doi:10.2337/dc09-2310.

[7] Kim TN, Park MS, Kim YJ, et al. Association of low muscle mass and combined low muscle mass and visceral obesity with low cardiorespiratory fitness. PLoS One 2014;9:e100118. doi:10.1371/journal.pone.0100118.

[8] Cooper LA, Clark BC. The vicious cycle of myostatin signaling in sarcopenic obesity: myostatin role in skeletal muscle growth, insulin signaling and implications for clinical trials. J Frailty Aging 2018;7:21–7. doi:10.14283/jfa.2017.33.

[9] Han DS, Chen YM, Lin SY, et al. Serum myostatin levels and grip strength in normal subjects and patients on maintenance haemodialysis. Clin Endocrinol (Oxf) 2011;75:857–63. doi:10.1111/j.1365-2265.2011.04120.x.

[10] Patel HP, Al-Shanti N, Davies LC, et al. Lean mass, muscle strength and function, and chronic disease in aged adults. J Exerc Nutrition Biochem 2016;20:46–50. doi:10.20463/jenb.2016.09.20.3.7.

[11] Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc 2002;50:889–96. doi:10.1046/j.1532-5415.2002.50202.x.

[12] Fess E. Grip strength. Clinical assessment recommendations, 2nd ed. Chicago: American Society of Hand Therapists; 1992. 41–45.

[13] Deng Y, Yang X, Wu J, et al. Decreased muscle mass and strength, increased body fat and negative health outcomes in patients with type 2 diabetes. J Diabetes Metab Syndr 2016;7:3–8. doi:10.1155/2016/515617.

[14] Auyeung TW, Lee JSW, Leung J, et al. Adiposity to muscle ratio (AMR) as a novel measure for clarifying evidence for sarcopenia in patients with diabetes mellitus. J Diabetes Investig 2019;10:1471–8. doi:10.1111/jdi.12851.

[15] Park SW, Goodpaster BH, Strotmeyer ES, et al. Decreased muscle mass, strength and quality in older adults with type 2 diabetes: the health, aging, and body composition study. J Am Med Dir Assoc 2016;17:846–51. doi:10.1016/j.jamda.2016.07.007.

[16] Cui M, Gang X, Wang G, et al. A cross-sectional study: associations between sarcopenia and clinical characteristics of patients with type 2 diabetes. Med (United States) 2020;99:18708. doi:10.1097/MD.0000000000001807.

[17] Bouchard C, Despres JP, Gagné E, et al. Increase in cardiovascular disease risk with low muscle mass in postmenopausal women. Arch Intern Med 2006;166:1474–80. doi:10.1001/archinte.166.11.1474.

[18] Liu JJ, Wong MDS, Toy WC, et al. Lower circulating irisin is associated with decreased muscle mass and insulin sensitivity via irisin-mediated cross talk between muscle and adipose tissues. Int J Obes 2016;40:434–42. doi:10.1038/ijo.2015.200.

[19] Xiao J, Purcell SA, Prado CM, et al. Fat mass to fat-free mass ratio reference values from NHANES III using bioelectrical impedance analysis. Clin Nutr 2018;37:2294–7.

[20] Bosy-Westphal A, Jensen B, Braun W, et al. Quantification of whole-body and segmental skeletal muscle mass using phase-sensitive 8-electrode medical bioelectrical impedance devices. Eur J Clin Nutr 2017;71:1061–7. doi:10.1038/ejcn.2017.27.

[21] Mayhew AJ, Amog K, Phillips S, et al. The prevalence of sarcopenia in community-dwelling older adults, an exploration of differences between studies and within definitions: A systematic review and meta-analyses. Age Aging 2019;48:48–56. doi:10.1093/ageing/afy106.

[22] Koo BK, Roh E, Yang YS, et al. Difference between old and young adults in contribution of β-cell function and sarcopenia in developing diabetes mellitus. J Diabetes Investig 2016;7:233–40. doi:10.1111/jdi.12392.

[23] Licinio A, Malmstrom TK. Frailty and sarcopenia as predictors of adverse health outcomes in persons with diabetes mellitus. J Am Med Dir Assoc 2016;17:846–51. doi:10.1016/j.jamda.2016.07.007.

[24] Park SW, Goodpaster BH, Strotmeyer ES, et al. Decreased muscle mass, strength and quality in older adults with type 2 diabetes: the health, aging, and body composition study. J Am Med Dir Assoc 2016;17:846–51. doi:10.1016/j.jamda.2016.07.007.

[25] Guo W, Zhang B, Wang X. Lower irisin levels in coronary artery disease: a meta-analysis. Minerva Endocrinol 2020;45:61–9. doi:10.23736/S0391-197717.02663-3.

[26] Liu JJ, Wong MDS, Toy WC, et al. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications 2013;27:365–9. doi:10.1016/j.jdiacomp.2013.03.002.

[27] Moreno-Navarrete JM, Ortega F, Serrano M, et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab 2013;98:E769–78. doi:10.1210/jc.2012-2749.

[28] Kurdiová T, Balaz M, Vican M, et al. Effects of obesity, diabetes and exercise on Fndc5 gene expression and irisin release in human skeletal muscle and adipose tissue: in vivo and in vitro studies. J Physiol 2014;592:1097–107. doi:10.1113/jphysiol.2013.264655.

[29] Dalal M, Ferrucci L, Sun K, et al. Elevated serum advanced glycation end products and poor grip strength in older community-dwelling women. Journals Gerontol - Ser A Biol Sci Med Sci 2009;64:132–7. doi:10.1093/gerona/glp188.

[30] Trierweiler H, Kisielewicz G, Jonasson TH, et al. Sarcopenia: a chronic complication of type 2 diabetes mellitus. Diabetol Metab Syndr 2018;10:1–9. doi:10.1186/s13098-018-0416-6.

[31] Donini LM, Busetto L, Bauer JM, et al. Critical appraisal of definitions and diagnostic criteria for sarcopenia based on a systematic review. Clin Nutr 2019;38:526–41. doi:10.1016/j.clnut.2019.04.025.

[32] Díaz J, Sanz D, Abadía B, et al. Sarcopenia in community-dwelling older adults: a cross-sectional study. J Frailty Aging 2018;7:21–7. doi:10.14283/jfa.2017.33.

[33] Ouizi K, Koolhas C, Schoufour J, et al. Association of anthropometric measures with fat and fat-free mass in the elderly: The Rotterdam study. Maturitas 2016;88:96–100. https://doi.org/10.1016/j.maturitas.2016.03.018.

[34] Prado CMM, Wells JCK, Smith SR, et al. Sarcopenic obesity: a critical appraisal of the current evidence. Clin Nutr 2012;31:583–601. doi:10.1016/j.clnu.2012.06.010.

[35] Auyeung TW, Lee JSW, Leung J, et al. Adiposity to muscle ratio predicts incident physical limitation in a cohort of 3153 older adults: an alternative measurement of sarcopenia and sarcopenic obesity. Age (Omaha) 2013;35:1377–85. doi:10.1186/s11357-012-9423-9.

[36] García-Fontana B, Reyes-García R, Morales-Santana S, et al. Relationship between myostatin and irisin in type 2 diabetes mellitus: a compensatory mechanism to an unfavourable metabolic state? Endocrine 2016;52:54–62. doi:10.1002/endo.2015-017588-8.

[37] Sunyer FX, Arosa V, Bach J, et al. Association of diabetic retinopathy with both sarcopenia and muscle quality in patients with type 2 diabetes: a cross sectional study. BMJ Open Diabetes Res Care 2017;5:1–7. doi:10.1136/bmjdrc-2017-000404.